Dupixent and Cancer: Status of the Proceedings [2025]

Introduction to the Status of the Proceedings in the Dupixent and Cancer Lawsuits

• Dupixent and Cancer: If you who were prescribed Dupixent and were subsequently diagnosed with T-Cell Lymphoma or experienced other severe Dupixent side effects, call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation as you may be eligible for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529

• Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases.

• Recent studies on Dupixent and Cancer:  Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.

• Potential Compensation: People who used Dupixent and were later diagnosed with CTCL may be eligible to file a Dupixent Cancer Lawsuit and potential entitled to substantial compensation. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

The Dupixent and Cancer Lawsuits are in the Early Stages

• Dupixent and Cancer Lawsuits:  Each Dupixent cancer lawsuit is in the early stages, with plaintiffs alleging the manufacturers failed to adequately warn about a potential link between the Dupixent and Cancer, specifically a type of skin cancer called cutaneous T-cell lymphoma (CTCL).

• Wave of Lawsuits: Multiple individual Dupixent and Cancer Lawsuits have been filed across the country, and while a consolidated multidistrict litigation (MDL) has not yet been established, it is possible in the future. These legal actions are based on emerging research and the experiences of patients who have developed Dupixent and Cancer.

• Who Is Eligible for a Dupixent Cancer Lawsuit? If you who were prescribed Dupixent and were subsequently diagnosed with T-Cell Lymphoma or experienced other severe Dupixent side effects, call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation as you may be eligible for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected].

Key Updates

• First Lawsuit Filed: In October 2025, the first known wrongful death lawsuit was filed in Tennessee by the family of a woman who died from T-cell lymphoma months after starting Dupixent injections.

• FDA Investigation: As of September 2025, the FDA is formally investigating Dupixent after receiving over 300 reports of CTCL and other lymphomas in patients using the drug. The FDA is evaluating whether to add new cancer warnings to the drug’s label.

• No Recall or Settlements Yet: There has been no FDA recall of Dupixent, and its label does not currently list lymphoma as a risk. As of November 2025, there have been no settlements or jury verdicts, and cases are proceeding individually, though they may be consolidated into multidistrict litigation (MDL) in the future.

• Upcoming Court Proceedings: The first lawsuit is scheduled for an initial case management conference in December 2025.

• Manufacturer Allegations: Lawsuits allege that the manufacturers, Sanofi and Regeneron, failed to warn patients and doctors about the potential risk of CTCL, preventing early detection and treatment. 

Supporting Evidence

• Clinical Research: Recent medical studies and data analyses have supported the potential link between Dupixent and CTCL: 

• •  2024 study in JAMA Dermatology found that Dupixent users had a significantly higher risk of developing CTCL compared to non-users.

• • A 2025 study in the European Respiratory Journal found that asthma patients treated with Dupixent had a 4.5-fold increased risk of CTCL compared to control groups. 

• Key Findings From Study:

• • Increased Risk of Specific Lymphoma Types: The study reported a hazard ratio (HR) of 4.58 (95% CI, 1.82–11.53) for T-cell and natural killer (NK)-cell lymphomas in Dupixent-treated patients compared to the control group.

• • Overall Lymphoma Risk: The overall risk of developing lymphoma (any type) was also significantly higher in the Dupixent group (HR 1.79).

• • Increased Risk with Longer Use: For patients who used Dupixent for longer than 16 weeks, the risk of mature T- and NK-cell lymphomas climbed more than 14-fold.

• • Lower Overall Mortality: Despite the increased lymphoma risk, the study noted that Dupixent-treated patients had significantly lower all-cause mortality compared to the ICS/LABA group.

• • Potential Wave of Lawsuits: Legal experts anticipate the number of lawsuits will rise as more patients and their families become aware of the potential connection between the medication and cancer. Individuals who developed CTCL or another T-cell lymphoma after using Dupixent may be eligible to file a claim.

• Research Calls for Patient Monitoring: This research, alongside other studies in patients with atopic dermatitis, has led to calls for long-term monitoring and further investigation into the potential link between Dupixent and lymphoma. There are ongoing legal investigations and an FDA review of the safety signals to determine if additional warnings are necessary.
  

What T-Cell Lymphoma Subtypes Have Been Reported in Lawsuits?

• Mycosis fungoides (MF): The most common form of CTCL, which often presents as skin patches or plaques that can be mistaken for eczema or psoriasis in its early stages.

• Sézary syndrome (SS): A more aggressive, leukemic variant of CTCL characterized by widespread skin redness (erythroderma), severe itching, and the presence of cancerous T-cells in the bloodstream.

• Anaplastic Large Cell Lymphoma: Both T-cell and null-cell types have been mentioned in adverse event reports submitted to the FDA.

• Angioimmunoblastic T-Cell Lymphoma: This subtype has also been included in FDA adverse event data linked to Dupixent use.

• Adult T-Cell Lymphoma/Leukemia: This specific T-cell malignancy has appeared in a small number of case reports.

• Peripheral T-Cell Lymphoma (PTCL): This broader category, which includes CTCL, has been cited in legal complaints and medical reports.

• Other rare types such as Lymphomatoid Papulosis and Subcutaneous Panniculitis-Like T-Cell Lymphoma have also been reported.